Wegovy obesity pill now available at pharmacies
The Wegovy pill launched Monday, and the starting dose is now available at pharmacies around the country with higher doses arriving by the end of the week.
The Food and Drug Administration approved the pill for obesity on Dec. 22. It’s also approved to reduce the risk of heart attack and stroke in patients who are obese or overweight.
The pill follows the blockbuster success of Novo Nordisk’s Wegovy injection, which has been on the market since 2021 and became so popular that it was in short supply until February 2025.
The pill version of the drug helped patients lose about as much weight as the injection. In a study published in the New England Journal of Medicine, a 25 milligram Wegovy pill led to a 13.6% reduction in weight on average over 64 weeks. Patients taking a placebo in the study lost 2.2% of their weight. For patients who stayed on the treatment, reduced their calorie intake and exercised, Novo Nordisk estimates they would have a 16.6% reduction in their weight.
However, patients need to take the Wegovy pill on an empty stomach and wait a half hour before eating anything else for the medicine to be properly absorbed. The most common side effects with the Wegovy pill are similar to the injection and include nausea, diarrhea and vomiting.
When Novo Nordisk announced its drug-pricing deal with the Trump administration in November, it promised to make the obesity pill available for $149 a month to patients not using their health insurance. However, that’s only the starting dose for the direct-to-consumer price. The higher doses will be available for $299 a month.
The price that affects insurance coverage, called a list price, is the same as the Wegovy injection: $1,349 a month.
Insurance coverage for obesity drugs became more restrictive in 2025, according to an analysis from GoodRx, a website that helps patients find discounts on prescription drugs. But Novo Nordisk says patients with insurance coverage can get the Wegovy pill for as low as $25 a month.
Although the Wegovy pill is the first of its kind to win FDA approval, Novo Nordisk’s Type 2 diabetes pill, Rybelsus, is already on the market. It contains the same active ingredient, semaglutide, but the doses are different.
Eli Lilly, which makes the Zepbound injection, applied to the FDA in late 2025 for approval of its competing obesity pill. The agency gave the company a voucher for a priority review and a decision could come early this year.
CIA turncoat Aldrich Ames, who sold U.S. secrets to the Soviets, dies in prison at 84
CIA turncoat Aldrich Ames, who betrayed Western intelligence assets to the Soviet Union and Russia in one of the most damaging breaches in U.S. history, has died in a Maryland prison. He was 84.
Trump Mobile’s golden phone remains nowhere to be found
A golden phone that President Donald Trump's family business promised to release last year remains mysteriously under wraps as the technology industry serves up a glut of new gadgets at CES in Las Vegas this week.
Security forces clash with protesters in Iran’s main market as death toll rises
The protest at the Grand Bazaar represented the latest signal that the demonstrations are likely to continue. Violence surrounding the protests has killed at least 36 people, activists abroad say.
Trump says US to get 30 million to 50 million barrels of oil from Venezuela at market price
Trump pledged to use proceeds from the sale of this oil "to benefit the people" of both countries.
Homeland Security plans 2,000 immigration officers in Minnesota
Homeland Security said Tuesday that it launched what it described as the largest immigration enforcement operation ever carried out, tied to allegations of fraud involving Somali residents in Minnesota.
Hungarian filmmaker Béla Tarr — known for bleak, existential movies — has died
Tarr's films were long, dark, and often abstract explorations of everyday life and politics.
